Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Tanaka, S.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(5)
+
-
Availability
Open access
(1)
+
-
Metadata Only
(4)
+
-
Creation Date
2017
(2)
+
-
2019
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(5)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(5)
+
-
Author
Heijde, D. van der
(5)
+
-
Takeuchi, T.
(5)
+
-
Tanaka, S.
(5)
+
-
Tanaka, Y.
(5)
+
-
Genant, H.K.
(4)
+
-
Nitta, T.
(4)
+
-
Okubo, N.
(4)
+
-
Soen, S.
(4)
+
-
Yamanaka, H.
(4)
+
-
Yoneda, T.
(4)
+
-
Show more
Language
en
(5)
+
-
Search results
(1 - 5 of 5)
show grid
show list
save search
Effects of denosumab in Japanese patients with rheumatoid arthritis treated with conventional antirheumatic drugs
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase
Consistent Inhibition of Joint Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis: Pooled Analysis of Phase 2 and 3 Studies
EFFECTS OF DENOSUMAB, A SUBCUTANEOUS RANKL INHIBITOR, ON THE PROGRESSION OF STRUCTURAL DAMAGE IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CSDMARDS: RESULTS FROM THE 12-MONTH DOUBLE BLIND PHASE 3, DESIRABLE STUDY